Diclofensine (Ro 8-4650) was developed by Hoffmann-La Roche in the 1970s[1] in the search for a new antidepressant. It was found that the (S)-isomer was responsible for activity.[2] Diclofensine is a stimulant drug which acts as a triple monoamine reuptake inhibitor,[3][4] primarily inhibiting the reuptake of dopamine[5] and norepinephrine,[6] with affinities (Ki) of 16.8 nM, 15.7 nM, and 51 nM for DAT, NET, and SERT (dopamine, norepinephrine and serotonin transporters), respectively.[7] It was found to be an effective antidepressant in human trials,[8][9][10] with relatively few side effects,[11] but was ultimately dropped from clinical development, possibly due to concerns about its abuse potential.[12][13]
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C17H17Cl2NO |
Molar mass | 322.23 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
Diclofensine is chemically a tetrahydroisoquinoline (THIQ) derivative, as is nomifensine.
The condensation of m-anisaldehyde [591-31-1] (1) with methylamine gives N-methyl-3-methoxybenzenemethanimine [16928-30-6]. Reduction of this Schiff-base intermediate with sodium borohydride gives (3-methoxybenzyl)methylamine [41789-95-1] (2). Alkylation of this with 3,4-dichlorophenacylbromide [2632-10-2] (3) would give CID:59580342 (4). Reduction of the benzoyl ketone with sodium borohydride gives the alcohol [802051-24-7] (5). Acid catalyzed intramolecular cyclization then completes the synthesis of the 4-aryl-THIQ derivative, diclofensine (6).
{{cite book}}
: CS1 maint: location (link)